Question
Does Tofacitinib Increase the Risk of Venous Thromboembolism in Patients with RA?
Conclusion
Recently, a link between venous thromboembolism (VTE) and Janus Kinase (JAK) inhibitors has emerged, causing the FDA to recommend a black box label for tofacitinib in 2019. New research, however, suggests that tofacitinib had similarly infrequent cases of VTE (<1 per 100) when compared with tumor necrosis factor inhibitors (TNFIs).
Recent Posts
- Surgery is no better than nonoperative treatment for Achilles tendon rupture in adults
- Another study fails to find PRP injections effective for adults with degenerative joint disease of the knee
- Short-term benefit from ultrasonography-guided steroid injection for Achilles tendinopathy
- How do ibuprofen, ketorolac, and diclofenac compare for the treatment of acute, nonradicular low back pain in adults?
- Is there an association between gastric cancer and the use of proton pump inhibitors?
Leave A Comment